Abstract: The present disclosure provides compounds for treating a variety of diseases, such as respiratory syncytial virus (RSV), HRV, hMPV, Ebola, Zika, West Nile, Dengue, and HCV.
Type:
Grant
Filed:
February 18, 2021
Date of Patent:
September 26, 2023
Assignee:
GILEAD SCIENCES, INC.
Inventors:
Gregory F. Chin, Byoung-Kwon Chun, Michael O. Clarke, Bindu Goyal, Hon C. Hui, Petr Jansa, Richard L. Mackman, Dustin S. Siegel, Hai Yang
Abstract: A compound of the general formula a process for the production of the compound and its use in electronic devices, especially electroluminescent devices. Improved efficiency, stability, manufacturability, or spectral characteristics of electroluminescent devices are provided when the compound of formula I is used as host material for phosphorescent emitters in electroluminescent devices.
Type:
Grant
Filed:
December 1, 2020
Date of Patent:
August 29, 2023
Assignee:
UDC IRELAND LIMITED
Inventors:
Thomas Schaefer, Flavio Luiz Benedito, Ute Heinemeyer, Nicolle Langer, Heinz Wolleb, Teresa Marina Figueira Duarte, Soichi Watanabe, Christian Lennartz, Gerhard Wagenblast, Annemarie Wolleb, Kristina Bardon
Abstract: Disclosed are compounds of Formula (I) or salts thereof, wherein Ring Het, R1, R2, R3, R4, R5, m, n, and p are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.
Type:
Grant
Filed:
March 21, 2022
Date of Patent:
August 29, 2023
Assignee:
Bristol-Myers Squibb Company
Inventors:
Alaric J. Dyckman, Dharmpal S. Dodd, Christopher P. Mussari, Trevor C. Sherwood, John L. Gilmore, Tasir Shamsul Haque, Brian K. Whiteley, David R. Tortolani, Shoshana L. Posy, John E. Macor, Louis J. Lombardo, Ramesh Kumar Sistla, Anupama Kandhi Ramachandra Reddy, Subramanya Hegde, Laxman Pasunoori, Sreekantha Ratna Kumar
Abstract: Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods that restore DNA binding affinity of p53 mutants. The compounds of the present disclosure can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.
Type:
Grant
Filed:
June 22, 2021
Date of Patent:
August 22, 2023
Assignee:
PMV PHARMACEUTICALS, INC.
Inventors:
Binh Vu, Romyr Dominique, Hongju Li, Bruce Fahr, Yi Chen
Abstract: Provided is a compound of Chemical Formula 1: HAr-L1-L2-Ar1 wherein: HAr is one of Chemical Formula A-1 or A-2: one of L1 and L2 is a substituted or unsubstituted monocyclic or polycyclic arylene group, or a substituted or unsubstituted monocyclic or polycyclic heteroarylene group, and the other one is a direct bond; and Ar1 is a cyano group, a substituted or unsubstituted phenyl group; a substituted or unsubstituted biphenyl group; a substituted or unsubstituted pyridinyl group; a substituted or unsubstituted triazinyl group; a substituted or unsubstituted polycyclic aryl group; or a substituted or unsubstituted polycyclic heteroaryl group, and an organic light emitting device comprising the same.
Type:
Grant
Filed:
March 22, 2019
Date of Patent:
August 22, 2023
Assignee:
LG CHEM, LTD.
Inventors:
Jungoh Huh, Dong Hoon Lee, Dong Uk Heo, Miyeon Han, Jae Tak Lee, Junghoon Yang, Heekyung Yun
Abstract: The present invention discloses a class of anti-influenza virus compounds, and the use thereof in the preparation of a drug for treating diseases associated with influenza viruses. In particular, the present invention discloses a compound represented by formula (I) and a pharmaceutically acceptable salt thereof.
Abstract: Provided herein are optionally substituted benzoimidazol-1,2-yl amides, pharmaceutical compositions comprising a therapeutically effective amount of such compounds and a pharmaceutically acceptable excipient, and methods of treating Kv7 associated diseases, such as, epilepsy, amyotrophic lateral sclerosis, various types of pain, hyperexcitability, a dyskinesia, dystonia, mania and tinnitus with such compounds and pharmaceutical compositions.
Type:
Grant
Filed:
January 7, 2022
Date of Patent:
August 15, 2023
Assignee:
Biohaven Therapeutics Ltd.
Inventors:
Michael E. Bozik, Scott S. Harried, Lynn Resnick, George T. Topalov, Justin K. Belardi, Charles A. Flentge, David A. Mareska, James S. Hale
Abstract: The present disclosure discloses an amine derivative and an organic electroluminescent device thereof, and relates to a technical field of organic photoelectric materials. The technical problem to be solved by the present disclosure is that the current light extraction material has poor thermal stability and the organic electroluminescent device has short service life. The amine derivative of the present disclosure is a diamine with a bridging group containing a fluorenyl group or a spirofluorenyl group, and the substituent group on N contains at least one benzoxazolyl group, benzothiazolyl group or benzimidazolyl group. The organic electroluminescent device of the present disclosure comprises an anode, an organic layer, a cathode and a light extraction layer, the organic layer is located between the anode and the cathode, and the light extraction layer comprises the amine derivative of Formula I according to the present disclosure.
Abstract: The present invention concerns a compound of formula (I), or one of its pharmaceutically acceptable salts, especially for use as inhibitors of the ERK kinase activity in particular ERK2 activity, it also concerns prodrugs of these compounds.
Type:
Grant
Filed:
March 29, 2021
Date of Patent:
July 25, 2023
Assignees:
AGV Discovery, Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Universite De Montpellier
Abstract: Disclosed herein are methods for treating neuropathic pain in a subject in need thereof. The methods include: administering to a subject in need thereof a therapeutically effective amount of an antagonist of P2Y14.
Type:
Grant
Filed:
July 23, 2020
Date of Patent:
July 25, 2023
Assignee:
Saint Louis University
Inventors:
Daniela Salvemini, Kenneth Alan Jacobson
Abstract: Methods and formulations are provided for treating spinobulbar muscular atrophy in a subject in need thereof. By administering a therapeutically effective amount of a selective androgen receptor modulator or a small molecule such as 1-[2-(4-methylphenoxy)ethyl]-2-[(2-phenoxyethyl)sulfanyl]-1H-benzimidazole or a derivative, prodrug, or pharmaceutically acceptable salt thereof, one or more symptoms of spinobulbar muscular atrophy can be ameliorated. The effective amount can be effective to prevent or delay loss of body weight, a loss of mobility, and/or a loss of physical strength in the subject; to prevent or delay neurogenic atrophy and/or to prevent a loss of spinal cord motor neurons in the subject; to restore the frequency of type I myofibers to normal levels for a healthy subject; and/or to reverse testicular atrophy in the subject.
Type:
Grant
Filed:
October 26, 2018
Date of Patent:
July 25, 2023
Assignee:
ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC.
Abstract: The present disclosure relates to compounds that are capable of modulating the WNT/Beta-Catenin pathway. The disclosure further relates to methods of treating colorectal cancer and other WNT/Beta-Catenin mediated cancers.
Type:
Grant
Filed:
January 30, 2019
Date of Patent:
July 25, 2023
Assignee:
The Regents of the University of California
Inventors:
Michael E. Jung, Xiaohong Chen, Cun-Yu Wang, Jiong Li, Jie Zheng
Abstract: The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.
Type:
Grant
Filed:
October 22, 2020
Date of Patent:
July 18, 2023
Assignee:
Gilead Sciences, Inc.
Inventors:
Stephen E. Ammann, Gediminas J. Brizgys, James S. Cassidy, Elbert Chin, Chienhung Chou, Jeromy J. Cottell, Michael Graupe, Chao-I Hung, Kavoos Kolahdouzan, Scott D. Schroeder, Nathan D. Shapiro, Daniel G. Shore, Suzanne M. Szewczyk, James G. Taylor, Rhiannon Thomas-Tran, Nathan E. Wright, Zheng-Yu Yang, Sheila M. Zipfel
Abstract: The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non alcoholic steatohepatitis (NASH).
Type:
Grant
Filed:
May 13, 2021
Date of Patent:
July 18, 2023
Assignee:
Gilead Sciences, Inc.
Inventors:
Barton W. Phillips, Doris T. Tang, Chandrasekar Venkataramani, Kin S. Yang, Anna Zagorska
Abstract: The present disclosure provides compounds of Formula (I). The compounds described herein may be useful in treating and/or preventing proliferative diseases (e.g., cancer). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.
Type:
Grant
Filed:
May 4, 2021
Date of Patent:
July 11, 2023
Assignees:
Children's Medical Center Corporation, Beth Israel Deaconess Medical Center, Inc.
Abstract: A compound of formula (I) wherein X is 0, C=0 or S; Y is N or CH; R2 and R4 are each independently H, —(CH2)pCOOH, —(CH2)pCON(R5)2 or —(CH2)pCOOC1-6alkyl; or R2 and R4 together form a 6-membered phenyl ring fused to the five membered ring; each R1 is independently selected from H, halo (e.g. fluoro or chloro), C6-10aryl, C7-12arylalkyl, C2-12 alkenyl; OC1-12 alkyl, OC2-12 alkenyl or a C1-12 alkyl group; each R5 is H or C1-6 alkyl; each p is 0 to 3; n is 1 to 4; or a salt, ester, solvate, N-oxide, or prodrug thereof, e.g. a salt thereof.
Abstract: The disclosure includes compounds of Formula (A): wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, and R12, j, k, m, n, Y, W, W1, W2, W3, V, L, Z1, Q1, Q2, Q3, and Q4, are defined herein. Also disclosed is a method for treating a neoplastic disease, an autoimmune disease, or a neurodegenerative disease with these compounds.
Abstract: The invention provides compounds of formula (I): where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.
Type:
Grant
Filed:
January 14, 2022
Date of Patent:
June 6, 2023
Assignee:
Theravance Biopharma R&D IP, LLC
Inventors:
Paul R. Fatheree, Gary E. L. Brandt, Cameron Smith, Steven D. E. Sullivan, Lori Jean Van Orden, Melanie A. Kleinschek, Glenn D. Crater
Abstract: The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula: where A, B, R1, X1, X2, and W are described herein.
Type:
Grant
Filed:
December 21, 2018
Date of Patent:
June 6, 2023
Assignee:
HiberCell, Inc.
Inventors:
Johan Lindström, Lars Boukharta Persson, Jenny Viklund, Edward A. Kesicki, Eugene R. Hickey, Markus K. Dahlgren, Aleksey I. Gerasyuto